These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 8247532

  • 1. Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage.
    Aloni-Grinstein R, Zan-Bar I, Alboum I, Goldfinger N, Rotter V.
    Oncogene; 1993 Dec; 8(12):3297-305. PubMed ID: 8247532
    [Abstract] [Full Text] [Related]

  • 2. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F.
    Cancer Res; 1996 Feb 01; 56(3):556-62. PubMed ID: 8564971
    [Abstract] [Full Text] [Related]

  • 3. Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins.
    Shaulsky G, Goldfinger N, Rotter V.
    Cancer Res; 1991 Oct 01; 51(19):5232-7. PubMed ID: 1717142
    [Abstract] [Full Text] [Related]

  • 4. Mutant human tumor suppressor p53 modulates the activation of mitogen-activated protein kinase and nuclear factor-kappaB, but not c-Jun N-terminal kinase and activated protein-1.
    Gulati AP, Yang YM, Harter D, Mukhopadhyay A, Aggarwal BB, Benzil DL, Whysner J, Albino AP, Murali R, Jhanwar-Uniyal M.
    Mol Carcinog; 2006 Jan 01; 45(1):26-37. PubMed ID: 16267831
    [Abstract] [Full Text] [Related]

  • 5. Wild-type murine p53 represses transcription from the murine c-myc promoter in a human glial cell line.
    Moberg KH, Tyndall WA, Hall DJ.
    J Cell Biochem; 1992 Jun 01; 49(2):208-15. PubMed ID: 1400626
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Identification and characterization of genes whose expressions are altered in rat 6 fibroblasts transformed by mutant p53(val135).
    Yam JW, Zheng JY, Hsiao WL.
    Biochem Biophys Res Commun; 1999 Dec 20; 266(2):472-80. PubMed ID: 10600527
    [Abstract] [Full Text] [Related]

  • 14. The proliferation-associated early response gene p22/PRG1 is a novel p53 target gene.
    Schäfer H, Trauzold A, Sebens T, Deppert W, Fölsch UR, Schmidt WE.
    Oncogene; 1998 May 14; 16(19):2479-87. PubMed ID: 9627114
    [Abstract] [Full Text] [Related]

  • 15. Transcriptional regulation of the Ig kappa gene by promoter-proximal pausing of RNA polymerase II.
    Raschke EE, Albert T, Eick D.
    J Immunol; 1999 Oct 15; 163(8):4375-82. PubMed ID: 10510378
    [Abstract] [Full Text] [Related]

  • 16. p53 involvement in activation of the cytokeratin 8 gene in tumor cell lines.
    Mukhopadhyay T, Roth JA.
    Anticancer Res; 1996 Oct 15; 16(1):105-12. PubMed ID: 8615594
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
    Liang Y, Wu J, Stancel GM, Hyder SM.
    J Steroid Biochem Mol Biol; 2005 Feb 15; 93(2-5):173-82. PubMed ID: 15860260
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.